Partnerships that get results: Global. Fluid. Connected. Join Us!

Loyola University Medical Center

Department of Medicine

Division of Hepatology

2160 S. First Ave
Mulcahy Center, Rm 1610

Maywood, IL 60153, USA

Email: hdahari@luc.edu

Phone: 708-216-4682

Fax: 708-216-6299

70th Annual Meeting of the American Association for the study of Liver Diseases

Boston, Ma, USA

November 8-12, 2019

Christopher Koh, Ben L. Da, Pallavi Surana, Amy Wen-Chun Huang, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chun-wei Lai, Farial Rahman, Julian Hercun, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Lambda Interferon for 24 weeks: Interim End-of-Treatment Results from the LIFT HDV Study. Hepatology 2019; accepted (Oral Late breaking).

Ohad Etzion, Sarah Duehren, Saeed Sadiq Hamid, Yoav Lurie, Edward Gane, Nimrah Bader, David Yardeni, Anat Nevo-Shor, SM Channa, Minaz Mawani, Om Parkash, Kyunghee Yang, Diane Longo, Susan L. Uprichard; Robert G. Gish, Scott J. Cotler; Jeffrey Glenn, David Apelian, Harel Dahari. Characterization of HDV, HBsAg and ALT kinetics under Peginterferon-Lambda Monotherapy: The Phase 2 LIMT Study. Hepatology 2019; accepted (Late breaking).

Swikriti Dasgupta, Michio Imamura, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari*, Kazuaki Chayama*. Modeling-based response-guided therapy under glecaprevir/pibrentasvir may optimize duration of therapy in patients with compensated cirrhosis. Hepatology 2019; Vol 70(Suppl1):931A.

Kevin Walsh, Marianne Martinello, Alexander Churkin, Sijia Lou, Tanya Applegate, Ohad Etzion, Susan L. Uprichard, Scott J. Cotler, Danny Barash, Gail Matthews, Harel Dahari. Modeling indicates 100% negative predictive value of achieving cure in subjects with recent HCV infection treated for 6 weeks with sofosbuvir and ribavirin: The DARE II Study. Hepatology 2019; Vol 70(Suppl1):969A-970A.

Elham Shirvani-Dastgerdi, Hannah Shanes, Andrew Berneshawi, Harel Dahari*, Alexander Ploss*.HDV RNA decline post inoculation in human NTCP transgenic mice is biphasic. Hepatology 2019; Vol 70(Suppl1):623A-624A. 70th Annual Meeting of the American Association for the study of Liver Diseases. Boston, Ma, USA, Nov 8-12, 2019

Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*.  Understanding early HBV kinetics during infection and treatment in primary human hepatocytes: a data-driven mathematical modeling approach. Hepatology 201; Vol 70(Suppl1):178A. (Oral talk)

Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Stephen Feinstone, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Simulation of HCV vaccine clinical trials reveals opportunities and challenges for candidate HCV vaccines. Hepatology 2019; Vol 70 (Suppl1):990A.

4th Workshop on viral dynamics

Paris, France

October 2019

Peter Kumberger, Karina Durso-Cain, Yannik Schälte, Theresa Fink, Harel Dahari, Jan Hasenauer, Susan L. Uprichard, Frederik Graw. Hepatitis C virus spread kinetics reveal varying contributions of transmission modes to infection dynamics. Abstract (Oral Talk)

26th International Symposium on HCV and related Viruses

Seoul, South Korea

October 5-8, 2019

Dahari H*, Etzion O*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Modeling based response guided therapy with DAA shortens treatment duration in HCV treated patients. (Oral Talk)

Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030.

2019 International HBV meeting “Molecular Biology of hepatitis B viruses

Melbourne, VIC, Australia

October 1-5, 2019

Masataka Tsuge, Ken Tsushima, Nobuhiko Hiraga, Takuro Uchida, Michio Imamura, C. Hayes Nelson, Harel Dahari, Susan L. Uprichard, Kazuaki Chayama. Analysis of the association between HBV infection and long term trends in intrahepatic gene expression.

Delaina May, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Harel Dahari, Kazuaki Chayama and Susan L Uprichard. HBV infection and spread in HepG2-NTCP cells initiated by low MOI inoculation in the absence of PEG.

17th International Conference of Numerical Analysis and Applied Mathematics (ICNAAM 2019)

Rhodes, Greece

September 23-28, 2019

Alexander Churkin, Vladimir Reinharz, Stephanie Lewkiewicz, Harel Dahari, Danny Barash. HCVMultiscaleFit: A Simulator for Parameter Estimation in Multiscale Models of Hepatitis C Virus Dynamics. (Oral talk)

SIAM Conference on the Life Sciences (LS18)

Minneapolis, Minnesota, USA

August 6-9, 2019

Danny Barash, Vladimir Reinharz, Alexander Churkin, Harel Dahari. Numerical Methods for Solving and Optimizing Multiscale Models of Hepatitis C Virus Dynamics (Oral talk)

Annual meeting of the Theoretical Biology and the Society for Mathematical Biology

Montreal, Canada

July 21-26, 2019

Mini-Symposia titled: “Hepatitis B viral dynamics: mathematical and numerical methods”.

Vladimir Reinharz, Danny Barash, and Harel Dahari. PDE modeling simulations and fitting methods for understanding hepatitis B virus infection in humanized mice. (Oral talk)

Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Kazuaki Chayama* Harel Dahari. Modeling hepatitis B virus infection in primary human hepatocytes. (Oral talk)

The International Liver Congress, 54th annual meeting of the European Association for the Study of the Liver

Vienna, Austria 

April 10-14, 2019

Yuji Ishida, Preeti Dubey, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*. Characterization of HBV kinetics during infection and treatment in primary human hepatocytes. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e701. https://doi.org/10.1016/S0618-8278(19)31399-4

Upendra Kumar, Rafaela VP Ribeiro, Susan L. Uprichard, Marcos Galasso, Atul Humar, Marcelo Cypel, Scott J. Cotler, Harel Dahari*, Jordan J. Feld*. Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e494–e495. https://doi.org/10.1016/S0618-8278(19)30971-5 (oral ePoster)

 

Louis Shekhtman, Scott J. Cotler, Susan L. Uprichard, Michel Bazinet, Victor Pantea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Adalbert Krawczyk, Andrew Vaillant, Harel Dahari. Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e463. https://doi.org/10.1016/S0618-8278(19)30913-2

2019 AASLD/EASL HCV Special Conference

Miami, FL, USA

February 1‐2, 2019

Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030

69th Annual Meeting of the American Association for the study of Liver Diseases

San Francisco, CA, USA, Nov 9-13, 2018

Etzion O*, Dahari H*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib O, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Response-guided therapy with DAA shortens treatment duration in 50% of HCV treated patients. Hepatology 2018; 68(6); 1468A – 1469A. (Late-Breaking # 34).https://doi.org/10.1002/hep.30353

25th International Symposium on HCV and related Viruses

Dublin, Ireland

Oct 8-11, 2018

Karina Durso-Cain, Peter Kumberger, Harel Dahari, Frederik Graw, Susan L. Uprichard.  Dissecting the contribution of cell-to-cell spread to HCV infection dynamics

Global Hepatitis Summit

Toronto, Canada

May 2018

Binhui Deng, Sijia Lou, Preeti Dubey, Ohad Etzion, Kazuaki Chayama, Susan L Uprichard, Mark Sulkowski, Scott J Cotler, Harel Dahari. Modeling time to cure after short-duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: The FOURward Study. (Travel award) Journal Viral Hepatitis, 2018, Vol 25 Suppl S2; pg 58. 

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.45_12923

VA Research Week

 May 14 – 18, 2018

Sarah Rahman, Kushal Shah, Veronica Loy, Cara Joyce, Harel Dahari, Roshani Naidu, Steve Scaglione and Susan L. Uprichard. Assessing Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

The International Liver Congress, 53rd annual meeting of the European Association for the Study of the Liver

Paris, France

April 11-15, 2018

Preeti Dubey, Christopher Koh, Pallavi Surana, Susan L. Uprichard,  Ma Ai Thanda Han, Nancy Fryzek, Gitanjali Subramanya, Devika Kapuria, Ohad Etzion, Varun Takyar, Yaron Rotman, Cihan Yurdaydin, Jeffrey S. Glenn, Scott J. Cotler, Theo Heller and Harel Dahari. Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV infected patients: A phase 2 LOWR HDV-3 study. Journal Hepatology 2018; Vol. 68, Suppl 1, S508

Upendra Kumar, Takuro Uchida, Atesmachew Hailegiorgis, Nobuhiko Hiraga, Kevin Walsh, Michio Imamura, Christopher Koh, Theo Heller, Jeffrey S. Glenn, Susan L. Uprichard, Kazuaki Chayama, Harel Dahari. Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling approach.  Journal Hepatology 2018; Vol. 68, Suppl 1, S783

 

Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi , Chise Tateno, Susan L. Uprichard, Kazuaki Chayama ,Harel Dahari. Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach. Journal Hepatology 2018; Vol. 68, Suppl 1, S782-S783

 

Louis Shekhtman, Nathaniel Borochov, Scott J. Cotler, Leeor Hershkovich, Susan L. Uprichard, Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant, Harel Dahari. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection. Journal Hepatology 2018; Vol. 68, Suppl 1, S508